Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BW-1014 in healthy adults
NCT05397119Phase 1Completed
- Sponsor
- BlueWillow Biologics
- Start
- Jul 2022
- Primary completion
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BW-1014 in pandemic influenza (5 arms), sponsored by BlueWillow Biologics. Primary endpoints: Number of Participants Reporting Local or Systemic Reactions at 1 hour, Number of Participants Reporting Solicited Reactions and General AEs at 7 days and 6 more. Started Jul 2022; status: completed.
02
Drugs
BW-1014
03
Conditions
pandemic influenza
Beyond the preview
Go deeper on NCT05397119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05397119.